EFFECTS OF AN ORALLY ACTIVE ANGIOTENSIN ANTAGONIST, LOSARTAN, ON THE CHRONICALLY CATHETERIZED SHEEP FETUS

被引：0

作者：

LUMBERS, ER ^{[1
]}

STEVENSON, KM ^{[1
]}

机构：

[1] UNIV NSW,SCH PHYSIOL & PHARMACOL,SYDNEY,NSW 2033,AUSTRALIA

来源：

FASEB JOURNAL | 1993年 / 7卷 / 03期

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：A445 / A445

页数：1

共 50 条

[31] Haemodynamic effects of losartan an angiotensin II receptor antagonist in patients with cirrhosis and portal hypertension. [J].

Tripathi, D ;

Therapondos, G ;

Lui, HF ;

Hayes, PC .

HEPATOLOGY, 2000, 32 (04) :527A-527A

[32] PHARMACOLOGY OF AN ACTIVE METABOLITE OF DUP-753 - AN ORALLY-ACTIVE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST [J].

TIMMERMANS, PBMWM ;

WONG, PC ;

PRICE, WA ;

CHIU, AT ;

DUNCIA, JV ;

CARINI, DJ ;

WEXLER, RR ;

JOHNSON, AL .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (03) :699-699

[33] LOSARTAN POTASSIUM, A NONPEPTIDE ANTAGONIST OF ANGIOTENSIN-II, CHRONICALLY ADMINISTERED PO DOES NOT READILY CROSS THE BLOOD-BRAIN-BARRIER [J].

BUI, JD ;

KIMURA, B ;

PHILLIPS, MI .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 219 (01) :147-151

[34] THE DISCOVERY OF DUP-753, A POTENT, ORALLY ACTIVE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST [J].

DUNCIA, JV ;

CARINI, DJ ;

CHIU, AT ;

JOHNSON, AL ;

PRICE, WA ;

WONG, PC ;

WEXLER, RR ;

TIMMERMANS, PBMWM .

MEDICINAL RESEARCH REVIEWS, 1992, 12 (02) :149-191

[35] PHARMACOLOGY OF SC-52458, AN ORALLY-ACTIVE, NONPEPTIDE ANGIOTENSIN-AT(1) RECEPTOR ANTAGONIST [J].

OLINS, GM ;

CORPUS, VM ;

CHEN, ST ;

MCMAHON, EG ;

PALOMO, MA ;

MCGRAW, DE ;

SMITS, GJ ;

NULL, CL ;

BROWN, MA ;

BITTNER, SE ;

KOEPKE, JP ;

BLEHM, DJ ;

SCHUH, JR ;

BAIERL, CJ ;

SCHMIDT, RE ;

COOK, CS ;

REITZ, DB ;

PENICK, MA ;

MANNING, RE ;

BLAINE, EH .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1993, 22 (04) :617-625

[36] Nonpeptide angiotensin II receptor antagonist: Pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan [J].

Wong, PC ;

Christ, DD ;

Wong, YN ;

Lam, GN .

PHARMACOLOGY, 1996, 52 (01) :25-29

[37] ANTIHYPERTENSIVE EFFICACY AND EFFECTS ON RENAL-FUNCTION OF L-158,809 - A NONPEPTIDE ORALLY ACTIVE ANGIOTENSIN-II ANTAGONIST [J].

KIVLIGHN, SD ;

GABEL, RA ;

SIEGL, PKS .

HYPERTENSION, 1992, 19 (01) :I135-I135

[38] Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts [J].

Wang, QD ;

Sjöquist, PO .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 380 (01) :13-21

[39] BIOCHEMICAL EFFECTS OF LOSARTAN, A NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST, ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS [J].

GOLDBERG, MR ;

BRADSTREET, TE ;

MCWILLIAMS, EJ ;

TANAKA, WK ;

LIPERT, S ;

BJORNSSON, TD ;

WALDMAN, SA ;

OSBORNE, B ;

PIVADORI, L ;

LEWIS, G ;

BLUM, R ;

HERMAN, T ;

ABRAHAM, PA ;

HALSTENSON, CN ;

LO, MW ;

LU, H ;

SPECTOR, R .

HYPERTENSION, 1995, 25 (01) :37-46

[40] DETERMINATION OF THE PRODUCTION AND METABOLIC-CLEARANCE RATES OF 1,25-DIHYDROXYVITAMIN-D3 IN THE PREGNANT SHEEP AND ITS CHRONICALLY CATHETERIZED FETUS BY PRIMED INFUSION TECHNIQUE [J].

ROSS, R ;

HALBERT, K ;

TSANG, RC .

PEDIATRIC RESEARCH, 1989, 26 (06) :633-638

← 1 2 3 4 5 →